Squarepoint Ops LLC bought a new position in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 473,216 shares of the biotechnology company's stock, valued at approximately $592,000. Squarepoint Ops LLC owned about 0.07% of OPKO Health at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Hennion & Walsh Asset Management Inc. lifted its stake in OPKO Health by 11.4% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 776,020 shares of the biotechnology company's stock worth $931,000 after purchasing an additional 79,525 shares during the last quarter. Moseley Investment Management Inc. bought a new stake in OPKO Health during the first quarter worth $41,000. Tidal Investments LLC bought a new position in shares of OPKO Health in the 1st quarter valued at $239,000. Rubric Capital Management LP lifted its stake in shares of OPKO Health by 800.0% in the 2nd quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company's stock valued at $55,528,000 after acquiring an additional 39,486,490 shares during the last quarter. Finally, Y.D. More Investments Ltd bought a new position in shares of OPKO Health in the 2nd quarter valued at $1,840,000. 64.63% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of research analysts have recently commented on the company. Piper Sandler reiterated an "overweight" rating and issued a $3.00 price target on shares of OPKO Health in a research note on Tuesday, September 17th. HC Wainwright reiterated a "buy" rating and issued a $3.00 price target on shares of OPKO Health in a research note on Thursday, September 26th. StockNews.com upgraded OPKO Health to a "sell" rating in a research note on Saturday, July 27th. Finally, Barrington Research reaffirmed an "outperform" rating and set a $2.25 target price on shares of OPKO Health in a report on Friday, September 20th.
Read Our Latest Analysis on OPK
Insider Activity at OPKO Health
In other OPKO Health news, major shareholder Opko Health, Inc. sold 25,000 shares of the firm's stock in a transaction on Friday, July 19th. The stock was sold at an average price of $32.29, for a total transaction of $807,250.00. Following the transaction, the insider now directly owns 3,383,403 shares in the company, valued at approximately $109,250,082.87. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders sold 636,444 shares of company stock valued at $21,125,127. 47.26% of the stock is owned by company insiders.
OPKO Health Trading Up 2.0 %
Shares of OPK stock traded up $0.03 during trading hours on Wednesday, hitting $1.50. 3,539,565 shares of the company were exchanged, compared to its average volume of 7,430,889. The firm has a market cap of $1.05 billion, a P/E ratio of -4.20 and a beta of 1.63. OPKO Health, Inc. has a fifty-two week low of $0.85 and a fifty-two week high of $1.75. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.36 and a current ratio of 1.63. The company has a 50 day simple moving average of $1.53 and a two-hundred day simple moving average of $1.38.
OPKO Health (NASDAQ:OPK - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.08. The company had revenue of $182.20 million during the quarter, compared to the consensus estimate of $184.70 million. OPKO Health had a negative net margin of 33.79% and a negative return on equity of 17.67%. The company's quarterly revenue was down 31.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.03) EPS. Equities analysts anticipate that OPKO Health, Inc. will post -0.29 EPS for the current year.
About OPKO Health
(
Free Report)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.
Further Reading
Before you consider OPKO Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OPKO Health wasn't on the list.
While OPKO Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
